Similar articles

Abstract: polycystic ovary syndrome (PCOS) is the most common metabolic and endocrine disorder in women. However, there is no agreement concerning how to diagnose and treat PCOS worldwide. Three practice guidelines or consensuses, including consensus from the European Society of Human Reproduction and Embryology (ESHRE)/the American Society for Reproductive Medicine (ASRM) in Rotterdam, diagnosis criteria and consensus in China, and clinical practice guideline from the Endocrine Society (ES) in the United States are widely recognized. The present paper may provide some guidance for clinical practice based on a comparative analysis of the above three practice guidelines or consensuses.

关于美国、欧洲和中国的多囊卵巢综合征临床指南或共识的比较分析

[1]Amr N, Abdel-Rahim HE, 2015. The effect of chromium supplementation on polycystic ovary syndrome in adolescents. J Pediatr Adolesc Gynecol, 28(2):114-118.

[2]The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group, 2012. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS). Hum Reprod, 27(1):14-24.

[3]Apter D, Butzow T, Laughlin G, 1993. Hyperandrogenism during Puberty and Adolescence, and Its Relationship to Reproductive Function in the Adult Female. Raven Press, p.265.

[4]Ashoush S, Abou-Gamrah A, Bayoumy H, et al., 2016. Chromium picolinate reduces insulin resistance in polycystic ovary syndrome: randomized controlled trial. J Obstet Gynaecol Res, 42(3):279-285.

[5]Avvad CK, Holeuwerger R, Silva VC, et al., 2001. Menstrual irregularity in the first postmenarchal years: an early clinical sign of polycystic ovary syndrome in adolescence. Gynecol Endocrinol, 15(3):170-177.

[6]Bazarganipour F, Ziaei S, Montazeri A, et al., 2013. Psychological investigation in patients with polycystic ovary syndrome. Health Qual Life Out, 11:141.

[7]Carmina E, Koyama T, Chang L, et al., 1992. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am J Obstet Gynecol, 167(6):1807-1812.

[8]Chen ZJ, Zhang YW, Liu JY, et al., 2011. Diagnosis criteria for polycystic ovary syndrome. Natl Health Fam Plan Commission China, 330:1-7 (in Chinese).

[9]Cosma M, Swiglo BA, Flynn DN, et al., 2008. Clinical review: insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab, 93(4):1135-1142.

[10]Cui LL, Zhao H, Zhang B, et al., 2013. Genotype-phenotype correlations of PCOS susceptibility SNPs identified by GWAS in a large cohort of Han Chinese women. Hum Reprod, 28(2):538-544.

[11]Dunaif A, Segal KR, Shelley DR, et al., 1992. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes, 41(10):1257-1266.

[12]Ehrmann DA, Barnes RB, Rosenfield RL, et al., 1999. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabet Care, 22(1):141-146.

[13]Endocrinology Group, Obstetrics and Gynecology Committee, China Medical Association, 2008. Consensus on the diagnosis and treatment for polycystic ovary syndrome. Chin J Obstet Gynecol, 43(7):553-555 (in Chinese).

[14]Fauser BC, Tarlatzis BC, Rebar RW, et al., 2012. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS):the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril, 97(1):28-38.

[15]Foroozanfard F, Jamilian M, Jafari Z, et al., 2015. Effects of zinc supplementation on markers of insulin resistance and lipid profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Exp Clin Endocrinol Diabet, 123(04):215-220.

[16]Galletly C, Moran L, Noakes M, et al., 2007. Psychological benefits of a high-protein, low-carbohydrate diet in obese women with polycystic ovary syndrome—a pilot study. Appetite, 49(3):590-593.

[17]Ghaneei A, Jowkar A, Ghavam MRH, et al., 2015. Cabergoline plus metformin therapy effects on menstrual irregularity and androgen system in polycystic ovary syndrome women with hyperprolactinemia. Iran J Reprod Med, 13(2):93-100.

[18]Goldzieher JW, Axelrod LR, 1963. Clinical and biochemical features of polycystic ovarian disease. Fertil Steril, 14(6):631-653.

[19]Harborne L, Fleming R, Lyall H, et al., 2003. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab, 88(9):4116-4123.

[20]Harrison CL, Lombard CB, Moran LJ, et al., 2011. Exercise therapy in polycystic ovary syndrome: a systematic review. Hum Reprod Update, 17(2):171-183.

[21]Joham AE, Teede HJ, Ranasinha S, et al., 2015. Prevalence of infertility and use of fertility treatment in women with polycystic ovary syndrome: data from a large community-based cohort study. J Womens Health, 24(4):299-307.

[22]Laven JS, Mulders AGMGJ, Visser JA, et al., 2004. Anti-mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab, 89(1):318-323.

[23]Legro RS, Kunselman AR, Dodson WC, et al., 1999. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab, 84(1):165-169.

[24]Legro RS, Arslanian SA, Ehrmann DA, et al., 2013. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab, 98(12):4565-4592.

[25]Legro RS, Brzyski RG, Diamond MP, et al., 2014. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med, 371(2):119-129.

[26]Li R, Zhang Q, Yang D, et al., 2013. Prevalence of polycystic ovary syndrome in women in China: a large community-based study. Hum Reprod, 28(9):2562-2569.

[27]Lobo RA, Granger LR, Paul WL, et al., 1983. Psychological stress and increases in urinary norepinephrine metabolites, platelet serotonin, and adrenal androgens in women with polycystic ovary syndrome. Am J Obstet Gynecol, 145(4):496-503.

[28]Luque-Ramirez M, Alpanes M, Sanchon R, et al., 2015. Referral bias in female functional hyperandrogenism and polycystic ovary syndrome. Eur J Endocrinol, 173(5):603-610.

[29]McCook JG, Bailey BA, Williams SL, et al., 2015. Differential contributions of polycystic ovary syndrome (PCOS) manifestations to psychological symptoms. J Behav Health Serv Res, 42(3):383-394.

[30]Melo AS, Ferriani RA, Navarro PA, 2015. Treatment of infertility in women with polycystic ovary syndrome: approach to clinical practice. Clinics, 70(11):765-769.

[31]Merkin SS, Phy JL, Sites CK, et al., 2016. Environmental determinants of polycystic ovary syndrome. Fertil Steril, 106(1):16-24.

[32]Milewicz A, 2013. Reimbursement of metformin for polycystic ovary syndrome. Endokrynol Pol, 64(5):409-414.

[33]Moll GW, Rosenfield RL, 1983. Plasma free testosterone in the diagnosis of adolescent polycystic ovary syndrome. J Pediatr, 102(3):461-464.

[34]Moran LJ, Hutchison SK, Norman RJ, et al., 2011. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev, 7:CD007506.

[35]Morgante G, Cappelli V, di Sabatino A, et al., 2015. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association. Minerva Ginecol, 67(5):457-463.

[36]Nandalike K, Agarwal C, Strauss T, et al., 2012. Sleep and cardiometabolic function in obese adolescent girls with polycystic ovary syndrome. Sleep Med, 13(10):1307-1312.

[37]Nidhi R, Padmalatha V, Nagarathna R, et al., 2012. Effect of a yoga program on glucose metabolism and blood lipid levels in adolescent girls with polycystic ovary syndrome. Int J Gynaecol Obstet, 118(1):37-41.

[38]Norman RJ, Mahabeer S, Masters S, 1995. Ethnic differences in insulin and glucose response to glucose between white and Indian women with polycystic ovary syndrome. Fertil Steril, 63(1):58-62.

[39]Norman RJ, Dewailly D, Legro RS, et al., 2007. Polycystic ovary syndrome. Lancet, 370(9588):685-697.

[40]Pau CT, Keefe CC, Welt CK, 2013. Cigarette smoking, nicotine levels and increased risk for metabolic syndrome in women with polycystic ovary syndrome. Gynecol Endocrinol, 29(6):551-555.

[41]Pigny P, Jonard S, Robert Y, et al., 2006. Serum anti-mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab, 91(3):941-945.

[42]Qu F, Li R, Sun W, et al., 2017. Use of electroacupuncture and transcutaneous electrical acupoint stimulation in reproductive medicine: a group consensus. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 18(3):186-193.

[43]Rivera R, Yacobson I, Grimes D, 1999. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol, 181(5):1263-1269.

[44]Roessler KK, Glintborg D, Ravn P, et al., 2012. Supportive relationships—psychological effects of group counselling in women with polycystic ovary syndrome (PCOS). Commun Med, 9(2):125-131.

[45]Rosenfield RL, Ehrmann DA, Littlejohn EE, 2015. Adolescent polycystic ovary syndrome due to functional ovarian hyperandrogenism persists into adulthood. J Clin Endocrinol Metab, 100(4):1537-1543.

[46]The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004a. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril, 81(1):19-25.

[47]The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004b. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod, 19(1):41-47.

[48]Samimi M, Jamilian M, Ebrahimi FA, et al., 2016. Oral carnitine supplementation reduces body weight and insulin resistance in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol, 84(6):851-857.

[49]Stabile G, Borrielli I, Artenisio AC, et al., 2014. Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome. J Pediatr Adolesc Gynecol, 27(3):177-182.

[50]Tan S, Hahn S, Benson S, et al., 2008. Psychological implications of infertility in women with polycystic ovary syndrome. Hum Reprod, 23(9):2064-2071.

[51]The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2008a. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril, 89(3):505-522.

[52]The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2008b. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod, 23(3):462-477.

[53]Thomson RL, Buckley JD, Moran LJ, et al., 2009. Comparison of aerobic exercise capacity and muscle strength in overweight women with and without polycystic ovary syndrome. BJOG, 116(9):1242-1250.

[54]Wang F, Pan J, Liu Y, et al., 2015. Alternative splicing of the androgen receptor in polycystic ovary syndrome. Proc Natl Acad Sci USA, 112(15):4743-4748.

[55]Wu Y, Robinson N, Hardiman P, et al., 2016. Acupuncture for treating polycystic ovary syndrome: guidance for future randomized controlled trials. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 17(3):169-180.

[56]Zhuang J, Liu Y, Xu L, et al., 2014. Prevalence of the polycystic ovary syndrome in female residents of Chengdu, China. Gynecol Obstet Invest, 77(4):217-223.